NCT00290979已完成3 期
Evaluation of Efficacy and Safety of HMR1964 (Insulin Glulisine) in Subjects With Type 1 Diabetes Mellitus; Insulin Lispro Controlled, Open, Randomized, Parallel Group, Non-inferiority Study, for 28 Weeks
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- Non-inferiority in the efficacy and safety of HMR1964 as compared with Insulin lispro
研究概览
简要总结
- To evaluate non-inferiority in the efficacy of HMR1964 as compared with Insulin lispro in terms of the change in HbA1C from baseline to endpoint.
- To compare the safety of HMR1964 with insulin lispro.
详细描述
- To compare HMR1964 with insulin lispro in terms of the change in HbA1C from baseline to week 12 and week 28; consecutive change in HbA1C by every 4 weeks, blood glucose parameters, symptomatic hypoglycemia and insulin doses (rapid-acting, basal and total).
- To collect 6-month safety data of HMR1964.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women with type 1 diabetes mellitus, an HbA1C range of >=6.0 - =<11.0%, and on a basal-bolus insulin regimen. They must have had at least 1 year of continuous insulin treatment at the date of informed consent.
排除标准
- •Subjects who received an oral hypoglycemic agent other than insulin within 4 weeks prior to informed consent
- •Subjects who received oral or intravenous corticosteroid within 4 weeks prior to informed consent
- •Subjects who were treated with another investigational product within 12 weeks prior to informed consent
- •Subjects with likelihood of requiring concomitant treatment during the study period with drugs not permitted by this study protocol
- •Subjects with clinically relevant cardiovascular, hepatic, neurologic, endocrine, active cancer, other serious complication or systemic disease making implementation of the protocol or interpretation of the study results difficult
- •Subjects who have undergone pancreatectomy or pancreas/islet cell transplant
- •Night shift workers
- •Subjects unlikely to comply with the study protocol, e.g., inability to periodic return for follow-up visits, and unlikelihood of completing the study
- •Subjects who have previously been treated with HMR1964
- •Subjects who are pregnant, breast feeding or wish to become pregnant during the study period
- •Female subjects who are possibly pregnant [female subjects of reproductive potential who have serum human chorionic gonadotropin (hCG) level > 0.7 mIU/mL as determined by central laboratory, SRL Medisearch Inc., during screening phase]
- •Subjects with diabetic retinopathy who received surgical treatments (laser photocoagulation or vitrectomy) within 24 weeks prior to informed consent, or who are expected to have these surgical treatments during the study period
- •Subjects with history of alcohol abuse
- •Subjects with hypersensitivity to insulin preparations
- •Subjects with impaired hepatic function (SGOT or SGPT ³=<80 IU/L determined by central laboratory, SRL Medisearch Inc., during screening phase) or impaired renal function (serum creatinine =<2.0 mg/dL determined by central laboratory, SRL Medisearch Inc., during screening phase)
- •Subjects who are judged by the investigator or subinvestigator as inappropriate as the subjects of this study for any other reason
结局指标
主要结局
Non-inferiority in the efficacy and safety of HMR1964 as compared with Insulin lispro
次要结局
- 6-month safety data
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.Diabetes, Type INCT00046150Sanofi59
已完成
3 期
Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00290927Sanofi390
已完成
1 期
A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 DiabetesType 1 DiabetesNCT03903016Sanofi90
已完成
2 期
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes SubjectsType 2 DiabetesNCT06688123Jiangsu HengRui Medicine Co., Ltd.275
已完成
不适用
Regular Insulin vs Rapid Insulin Delivered by V-GoType 2 Diabetes MellitusType 2 DiabetesNCT03495908East Coast Institute for Research136